Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts

被引:202
作者
Eikenes, L
Bruland, OS
Brekken, C
Davies, CDL
机构
[1] Norwegian Univ Sci & Technol, Dept Phys, N-7491 Trondheim, Norway
[2] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7491 Trondheim, Norway
[3] Norwegian Radium Hosp, Dept Radiotherapy & Oncol, Oslo, Norway
关键词
D O I
10.1158/0008-5472.CAN-03-1472
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer therapy based on tumor-selective macromolecules may fail due to the elevated interstitial fluid pressure (IFP) that reduces the transvascular and interstitial convection in solid tumors. Modulation of the tumor extracellular matrix (ECM) may reduce IFP and enhance transvascular filtration and interstitial transport of macromolecules. We therefore measured the effect of the ECM-degrading enzyme collagenase on IFP and microvascular pressure (MVP) in human osteosarcoma xenografts using the wick-in-needle and micropipette methods, respectively. The tumor uptake and distribution of a systemically administered osteosarcoma-associated monoclonal antibody (TP-3) after i.v. injection of collagenase were analyzed using confocal laser scanning microscopy. Collagenase (0.1%)reduced both IFP (45%) and MVP (60%), but the kinetics of the recoveries differed, because MVP had recovered by the time IFP reached its minimum level. Thus, collagenase increased the transcapillary pressure gradient, inducing a 2-fold increase in the tumor uptake and improving the distribution of the monoclonal antibody, which was localized further into the tumor. To study the mechanism of the reduction in MVP, mean arterial blood pressure was measured and found not to he affected by the collagenase treatment. The reduction in MVP was rather due to reduced vascular resistance because microvascular-associated collagen was totally or partially disintegrated. Although collagenase may favor metastasis and thus not be clinically relevant, this study shows proof of principle that degradation of the ECM leads to a favorable change in the transvascular pressure gradient, thereby increasing antibody penetration and binding to tumor cells.
引用
收藏
页码:4768 / 4773
页数:6
相关论文
共 33 条
[1]  
BAUMGARTNER G, 1988, REG CANCER TREAT, V1, P55
[2]  
BAYER EA, 1990, METHOD ENZYMOL, V184, P159
[3]  
BETZ P, 1993, INT J LEGAL MED, V106, P34
[4]  
BOUCHER Y, 1990, CANCER RES, V50, P4478
[5]  
BOUCHER Y, 1992, CANCER RES, V52, P5110
[6]  
Brekken C, 2000, ANTICANCER RES, V20, P3513
[7]  
Brekken C, 2000, ANTICANCER RES, V20, P3503
[8]  
BRULAND OS, 1988, CANCER RES, V48, P5302
[9]  
Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO
[10]  
2-C